To examine the indicators of success in reimbursement application in Australia made by the Pharmaceutical Benefit Advisory Committee (PBAC), and describe the rationale behind it. Of interest is whether or not listing on the Pharmaceutical Benefit Scheme (PBS) is recommended based on the clinical evidence, the cost-effectiveness outcomes, political will, and whether there is clarity in the recommendations made for the subsidisation of drugs on the PBS. This examination is conducted in order to shed light on the basis of decision making and the impact of economic evaluations.
Makarounas-Kirchmann, K., Ademi, Z., & Kirchmann, M. (2012). Pharmaceutical benefit advisory committee acceptability threshold results 2005-2011. Value in Health, 15(7), 622 - 622. https://doi.org/10.1016/j.jval.2012.08.121